<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Virol</journal-id><journal-id journal-id-type="iso-abbrev">J. Med. Virol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1096-9071</journal-id><journal-id journal-id-type="publisher-id">JMV</journal-id><journal-title-group><journal-title>Journal of Medical Virology</journal-title></journal-title-group><issn pub-type="ppub">0146-6615</issn><issn pub-type="epub">1096-9071</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7436731</article-id><article-id pub-id-type="doi">10.1002/jmv.26397</article-id><article-id pub-id-type="publisher-id">JMV26397</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Comparative analysis of antiviral efficacy of FDA&#x02010;approved drugs against SARS&#x02010;CoV&#x02010;2 in human lung cells</article-title><alt-title alt-title-type="left-running-head">KO <sc>et al.</sc></alt-title></title-group><contrib-group><contrib id="jmv26397-cr-0001" contrib-type="author"><name><surname>Ko</surname><given-names>Meehyun</given-names></name><xref ref-type="aff" rid="jmv26397-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jmv26397-cr-0002" contrib-type="author"><name><surname>Jeon</surname><given-names>Sangeun</given-names></name><xref ref-type="aff" rid="jmv26397-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jmv26397-cr-0003" contrib-type="author"><name><surname>Ryu</surname><given-names>Wang&#x02010;Shick</given-names></name><xref ref-type="aff" rid="jmv26397-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jmv26397-cr-0004" contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Seungtaek</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3954-5908</contrib-id><xref ref-type="aff" rid="jmv26397-aff-0001">
<sup>1</sup>
</xref><address><email>seungtaek.kim@ip-korea.org</email></address></contrib></contrib-group><aff id="jmv26397-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Zoonotic Virus Laboratory</named-content>
<institution>Institut Pasteur Korea</institution>
<city>Seongnam</city>
<country country="KR">Korea</country>
</aff><aff id="jmv26397-aff-0002">
<label><sup>2</sup></label>
<institution>CEO Office, Institut Pasteur Korea</institution>
<city>Seongnam</city>
<country country="KR">Korea</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Seungtaek Kim, PhD, Zoonotic Virus Laboratory, Institut Pasteur Korea, 16, Daewangpangyo&#x02010;ro 712 beon&#x02010;gil, Bundang&#x02010;gu, Seongnam&#x02010;si, Gyeonggi&#x02010;do 13488, South Korea.<break/>
Email: <email>seungtaek.kim@ip-korea.org</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>8</month><year>2020</year></pub-date><elocation-id>10.1002/jmv.26397</elocation-id><history><date date-type="received"><day>27</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>30</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Wiley Periodicals LLC <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 Wiley Periodicals LLC</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JMV-9999-na.pdf"/><abstract><title>Abstract</title><p>Drug repositioning represents an effective way to control the current COVID&#x02010;19 pandemic. Previously, we identified 24 FDA&#x02010;approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC<sub>50</sub>&#x02009;=&#x02009;0.0022&#x02009;&#x000b5;M).</p></abstract><kwd-group><kwd id="jmv26397-kwd-0001">COVID&#x02010;19</kwd><kwd id="jmv26397-kwd-0002">drug repositioning</kwd><kwd id="jmv26397-kwd-0003">FDA&#x02010;approved drug</kwd><kwd id="jmv26397-kwd-0004">SARS&#x02010;CoV&#x02010;2</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Research Foundation of Korea </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003725</institution-id></institution-wrap></funding-source><award-id>NRF&#x02010;2017M3A9G6068245</award-id><award-id>NRF&#x02010;2020M3E9A1041756</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="6"/><word-count count="2640"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.7 mode:remove_FC converted:19.08.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="jmv26397-cit-0019">
<string-name>
<surname>Ko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jeon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ryu</surname>
<given-names>W&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>. <article-title>Comparative analysis of antiviral efficacy of FDA&#x02010;approved drugs against SARS&#x02010;CoV&#x02010;2 in human lung cells</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>;<fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.26397</pub-id>
<pub-id pub-id-type="pmid">31502247</pub-id></mixed-citation>
</p></notes></front><body><sec id="jmv26397-sec-0010"><label>1</label><title>INTRODUCTION</title><p>Coronavirus disease 2019 (COVID&#x02010;19) is an emerging infectious disease caused by a coronavirus.<xref rid="jmv26397-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> The causative virus was named as severe acute respiratory syndrome coronavirus 2 (SARS&#x02010;CoV&#x02010;2) because it is very similar to SARS&#x02010;CoV (79.5%) and this virus belongs to the <italic>Betacoronavirus</italic> genus within the <italic>Coronaviridae</italic> family.<xref rid="jmv26397-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> Both SARS&#x02010;CoV and Middle East respiratory syndrome coronavirus (MERS&#x02010;CoV) also belong to the same <italic>Betacoronavirus</italic> genus.</p><p>Neither vaccine nor therapeutic has been developed for SARS&#x02010; and MERS&#x02010;CoV and the current standard of care for the patients with COVID&#x02010;19 is just supportive care. However, numerous clinical trials are ongoing globally with Food and Drug Administration (FDA)&#x02010;approved drugs as drug repositioning programs (<ext-link ext-link-type="uri" xlink:href="https://www.covid-trials.org/">https://www.covid-trials.org/</ext-link>). Among these drugs, (hydroxy)chloroquine, lopinavir/ritonavir, and remdesivir are those that are the most frequently being tested worldwide due to the well&#x02010;known in vitro antiviral effects on both MERS&#x02010; and SARS&#x02010;CoV and even on SARS&#x02010;CoV&#x02010;2.<xref rid="jmv26397-bib-0003" ref-type="ref">
<sup>3</sup>
</xref>
</p><p>Previously, we identified a total of 24 potential antiviral drug candidates from FDA&#x02010;approved drugs using Vero cells.<xref rid="jmv26397-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Since antiviral efficacy could be altered in different cell lines, we developed a new image&#x02010;based antiviral screening assay with Calu&#x02010;3 cells, a well&#x02010;known human lung cell line,<xref rid="jmv26397-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> and compared the antiviral efficacy of the antiviral candidates in between Vero and Calu&#x02010;3 cells.</p></sec><sec sec-type="materials-and-methods" id="jmv26397-sec-0020"><label>2</label><title>MATERIALS AND METHODS</title><sec id="jmv26397-sec-0030"><label>2.1</label><title>Virus and cells</title><p>Calu&#x02010;3 used in this study is a clonal isolate, which shows higher growth rate compared with the parental Calu&#x02010;3 obtained from the American Type Culture Collection (ATCCHTB&#x02010;55). Calu&#x02010;3 was maintained at 37&#x000b0;C with 5% CO<sub>2</sub> in Eagle's Minimum Essential Medium (EMEM, ATCC), supplemented with 10% heat&#x02010;inactivated fetal bovine serum (FBS) and 1X Antibiotic&#x02010;Antimycotic solution (Gibco). SARS&#x02010;CoV&#x02010;2 (&#x003b2;CoV/KOR/KCDC03/2020) was provided by Korea Centers for Disease Control and Prevention (KCDC), and was propagated in Vero cells. Viral titers were determined by plaque assays in Vero cells. All experiments using SARS&#x02010;CoV&#x02010;2 were performed at Institut Pasteur Korea in compliance with the guidelines of the KNIH, using enhanced biosafety level 3 (BSL&#x02010;3) containment procedures in laboratories approved for use by the KCDC.</p></sec><sec id="jmv26397-sec-0040"><label>2.2</label><title>Reagents</title><p>Chloroquine diphosphate (CQ; C6628) was purchased from Sigma&#x02010;Aldrich (St. Louis, MO), lopinavir (LPV; S1380) was purchased from SelleckChem (Houston, TX), and remdesivir (HY&#x02010;104077) was purchased from MedChemExpress (Monmouth Junction, NJ). Chloroquine was dissolved in Dulbecco's Phosphate&#x02010;Buffered Saline (DPBS; Welgene), and all other reagents were dissolved in dimethyl sulfoxide (DMSO) for the screening. Anti&#x02010;SARS&#x02010;CoV&#x02010;2 N protein antibody was purchased from Sino Biological Inc (Beijing, China). Alexa Fluor 488 goat anti&#x02010;rabbit IgG (H&#x02009;+&#x02009;L) secondary antibody and Hoechst 33342 were purchased from Molecular Probes. Paraformaldehyde (PFA) (32% aqueous solution) and normal goat serum were purchased from Electron Microscopy Sciences (Hatfield, PA) and Vector Laboratories, Inc (Burlingame, CA), respectively.</p></sec><sec id="jmv26397-sec-0050"><label>2.3</label><title>Dose&#x02010;response curve analysis by immunofluorescence</title><p>Ten&#x02010;point dose&#x02010;response curves (DRCs) were generated for each drug. Calu&#x02010;3 cells were seeded at 2.0&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells per well in EMEM, supplemented with 10% FBS and 1X Antibiotic&#x02010;Antimycotic solution (Gibco) in black, 384&#x02010;well, &#x003bc;Clear plates (Greiner Bio&#x02010;One), 24&#x02009;hours before the experiment. Ten&#x02010;point DRCs were generated, with compound concentrations ranging from 0.1 to 50&#x02009;&#x003bc;M. For viral infection, plates were transferred into the BSL&#x02010;3 containment facility and SARS&#x02010;CoV&#x02010;2 was added at a multiplicity of infection of 0.1. The cells were fixed at 24 hpi with 4% PFA and analyzed by immunofluorescence. The acquired images were analyzed using in&#x02010;house software to quantify cell numbers and infection ratios, and antiviral activity was normalized to positive (mock) and negative (0.5% DMSO) controls in each assay plate. DRCs were generated in Prism7 (GraphPad) software, with dose&#x02010;response&#x02010;inhibition nonlinear regression analysis. Half maximal Inhibitory concentration (IC<sub>50</sub>) and half maximal cytotoxic concentration (CC<sub>50</sub>) values were obtained with the identical analysis method. Mean values of independent duplicate experiments were used for analysis. Each assay was controlled by Z'&#x02010;factor and the coefficient of variation in percent (%CV).</p></sec></sec><sec id="jmv26397-sec-0060"><label>3</label><title>RESULTS AND DISCUSSION</title><p>In our previous drug repositioning study, we identified a total of 24 potential antiviral drug candidates from FDA&#x02010;approved drugs.<xref rid="jmv26397-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> These drugs showed very potent antiviral efficacy against SARS&#x02010;CoV&#x02010;2 (0.1&#x02009;&#x000b5;M&#x02009;&#x0003c;&#x02009;IC<sub>50</sub>&#x02009;&#x0003c;&#x02009;10&#x02009;&#x000b5;M) in the experiments using Vero cells. Although Vero cells are commonly used for virus infection and propagation, they were originally isolated from the African green monkey kidney, thus do not represent the respiratory cells from the human lung, which is the main target tissue for SARS&#x02010;CoV&#x02010;2 infection. In this study, we compared the antiviral efficacy of the 24 potential antiviral drug candidates against SARS&#x02010;CoV&#x02010;2 using Calu&#x02010;3 human lung cells. Calu&#x02010;3 was originally isolated from human lung adenocarcinoma and is a well&#x02010;characterized epithelial cell line.<xref rid="jmv26397-bib-0005" ref-type="ref">
<sup>5</sup>
</xref>
</p><p>In order to conduct the DRC analysis with drugs, Calu&#x02010;3 cells were treated with each drug candidate 1&#x02009;hour before SARS&#x02010;CoV&#x02010;2 infection. The infected cells were incubated for 24&#x02009;hours and then fixed for immunofluorescence. Both viral N protein and host cell nucleus were stained by immunofluorescence and the quantitative analysis to measure the inhibition of virus infection and the cell viability due to drug treatment was conducted using our in&#x02010;house Image Mining software.</p><p>The DRC analysis of the reference drugs (ie, chloroquine, lopinavir, and remdesivir) (Figure&#x000a0;<xref rid="jmv26397-fig-0001" ref-type="fig">1</xref>) showed differences in IC<sub>50</sub> in between Vero and Calu&#x02010;3 cells. While the IC<sub>50</sub> values of both chloroquine and lopinavir increased by approcimately 10 folds and 2 folds, respectively (Table&#x000a0;<xref rid="jmv26397-tbl-0001" ref-type="table">1</xref>), the IC<sub>50</sub> of remdesivir rather decreased by 10 folds compared with that with Vero cells, perhaps due to the low metabolic capacity or prodrug activation rate in Vero cells<xref rid="jmv26397-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> (Table&#x000a0;<xref rid="jmv26397-tbl-0002" ref-type="table">2</xref>). These discrepancies might in part account for the different outcomes from numerous clinical trials using chloroquine, lopinavir, and remdesivir. So far, the treatment with (hydroxy)chloroquine or lopinavir/ritonavir did not show any promising results concerning the COVID&#x02010;19 treatment<xref rid="jmv26397-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="jmv26397-bib-0008" ref-type="ref">
<sup>8</sup>
</xref>, <xref rid="jmv26397-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>; however remdesivir seems to be effective for treatment of patients with COVID&#x02010;19 in certain clinical settings.<xref rid="jmv26397-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</p><fig fig-type="Figure" xml:lang="en" id="jmv26397-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Dose&#x02010;response curve (DRC) of reference drugs. Three reference drugs&#x02014;remdesivir, lopinavir, and chloroquine&#x02014;were serially diluted by two folds to generate a 10&#x02010;point DRC. Graphs are shown on the right and representative images at each point are shown on the left. The red line indicates cell viability, and the blue line indicates inhibition of severe acute respiratory syndrome coronavirus 2 (SARS&#x02010;CoV&#x02010;2) infection. SARS&#x02010;CoV&#x02010;2 infectivity was measured by immunofluorescence of SARS&#x02010;CoV&#x02010;2 N protein. Each point is a mean of duplicate experiments&#x02009;&#x000b1;&#x02009;standard deviation. Half maximal inhibitory concentration (IC<sub>50</sub>), half maximal cytotoxic concentration (CC<sub>50</sub>), and selective index (SI) are noted below each graph. Nucleus is shown in red, and viral N protein is shown in green</p></caption><graphic id="nlm-graphic-1" xlink:href="JMV-9999-na-g001"/></fig><table-wrap id="jmv26397-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 1</label><caption><p>List of drugs with increased IC<sub>50</sub> in Calu&#x02010;3 cells</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th valign="bottom" rowspan="1" colspan="1">Drug name</th><th valign="bottom" rowspan="1" colspan="1">IC<sub>50</sub> in Vero, &#x000b5;M<xref ref-type="fn" rid="jmv26397-tbl1-note-0002">a</xref>
</th><th valign="bottom" rowspan="1" colspan="1">IC<sub>50</sub> in Calu&#x02010;3, &#x000b5;M<xref ref-type="fn" rid="jmv26397-tbl1-note-0003">b</xref>
</th><th valign="bottom" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody valign="top"><tr><td colspan="4" valign="top" rowspan="1">Fold change &#x0003e;4</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Tetrandrine</td><td valign="top" rowspan="1" colspan="1">3</td><td valign="top" rowspan="1" colspan="1">13.5</td><td valign="top" rowspan="1" colspan="1">4.50</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Berbamine hydrochloride</td><td valign="top" rowspan="1" colspan="1">7.87</td><td valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td valign="top" rowspan="1" colspan="1">6.35</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Abemaciclib</td><td valign="top" rowspan="1" colspan="1">6.62</td><td valign="top" rowspan="1" colspan="1">43.7</td><td valign="top" rowspan="1" colspan="1">6.60</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cepharanthine</td><td valign="top" rowspan="1" colspan="1">4.47</td><td valign="top" rowspan="1" colspan="1">30</td><td valign="top" rowspan="1" colspan="1">6.71</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gilteritinib</td><td valign="top" rowspan="1" colspan="1">6.76</td><td valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td valign="top" rowspan="1" colspan="1">7.40</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chloroquine</td><td valign="top" rowspan="1" colspan="1">7.28</td><td valign="top" rowspan="1" colspan="1">69.2</td><td valign="top" rowspan="1" colspan="1">9.51</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Amodiaquine dihydrochloride</td><td valign="top" rowspan="1" colspan="1">5.15</td><td valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td valign="top" rowspan="1" colspan="1">9.71</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mefloquine</td><td valign="top" rowspan="1" colspan="1">4.33</td><td valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td valign="top" rowspan="1" colspan="1">11.55</td></tr><tr><td colspan="4" valign="top" rowspan="1">Fold change &#x0003e;2</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Salinomycin sodium</td><td valign="top" rowspan="1" colspan="1">0.24</td><td valign="top" rowspan="1" colspan="1">0.5</td><td valign="top" rowspan="1" colspan="1">2.08</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lopinavir</td><td valign="top" rowspan="1" colspan="1">9.12</td><td valign="top" rowspan="1" colspan="1">21.7</td><td valign="top" rowspan="1" colspan="1">2.38</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ciclesonide</td><td valign="top" rowspan="1" colspan="1">4.33</td><td valign="top" rowspan="1" colspan="1">10.64</td><td valign="top" rowspan="1" colspan="1">2.46</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Proscillaridin</td><td valign="top" rowspan="1" colspan="1">2.04</td><td valign="top" rowspan="1" colspan="1">5.95</td><td valign="top" rowspan="1" colspan="1">2.92</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Niclosamide</td><td valign="top" rowspan="1" colspan="1">0.28</td><td valign="top" rowspan="1" colspan="1">0.84</td><td valign="top" rowspan="1" colspan="1">3.00</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Anidulafungin</td><td valign="top" rowspan="1" colspan="1">4.64</td><td valign="top" rowspan="1" colspan="1">17.23</td><td valign="top" rowspan="1" colspan="1">3.71</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Digoxin</td><td valign="top" rowspan="1" colspan="1">0.19</td><td valign="top" rowspan="1" colspan="1">0.72</td><td valign="top" rowspan="1" colspan="1">3.79</td></tr><tr><td style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bazedoxifene</td><td valign="top" rowspan="1" colspan="1">3.44</td><td valign="top" rowspan="1" colspan="1">12.63</td><td valign="top" rowspan="1" colspan="1">3.67</td></tr></tbody></table><table-wrap-foot><fn id="jmv26397-tbl1-note-0001"><p>Abbreviation: IC<sub>50</sub>, half maximal inhibitory concentration.</p></fn><fn id="jmv26397-tbl1-note-0002"><label>a</label><p>IC<sub>50</sub> was determined by Jeon et al.<xref rid="jmv26397-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>
</p></fn><fn id="jmv26397-tbl1-note-0003"><label>b</label><p>IC<sub>50</sub> was determined in this study.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="jmv26397-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 2</label><caption><p>List of drugs with decreased IC<sub>50</sub> in Calu&#x02010;3 cells</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th valign="bottom" rowspan="1" colspan="1">Drug name</th><th valign="bottom" rowspan="1" colspan="1">IC<sub>50</sub> in Vero, &#x000b5;M<xref ref-type="fn" rid="jmv26397-tbl2-note-0002">a</xref>
</th><th valign="bottom" rowspan="1" colspan="1">IC<sub>50</sub> in Calu&#x02010;3, &#x000b5;M<xref ref-type="fn" rid="jmv26397-tbl2-note-0003">b</xref>
</th><th valign="bottom" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody valign="top"><tr><td valign="top" rowspan="1" colspan="1">Nafamostat mesylate</td><td valign="top" rowspan="1" colspan="1">13.88</td><td valign="top" rowspan="1" colspan="1">0.0022</td><td valign="top" rowspan="1" colspan="1">0.00016</td></tr><tr><td valign="top" rowspan="1" colspan="1">Camostat mesylate</td><td valign="top" rowspan="1" colspan="1">&#x0003e;50</td><td valign="top" rowspan="1" colspan="1">0.187</td><td valign="top" rowspan="1" colspan="1">0.00374</td></tr><tr><td valign="top" rowspan="1" colspan="1">Remdesivir</td><td valign="top" rowspan="1" colspan="1">11.41</td><td valign="top" rowspan="1" colspan="1">1.3</td><td valign="top" rowspan="1" colspan="1">0.11</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hydroxyprogesterone caproate</td><td valign="top" rowspan="1" colspan="1">6.3</td><td valign="top" rowspan="1" colspan="1">3.87</td><td valign="top" rowspan="1" colspan="1">0.61</td></tr><tr><td valign="top" rowspan="1" colspan="1">Digitoxin</td><td valign="top" rowspan="1" colspan="1">0.23</td><td valign="top" rowspan="1" colspan="1">0.16</td><td valign="top" rowspan="1" colspan="1">0.70</td></tr><tr><td valign="top" rowspan="1" colspan="1">Cyclosporine</td><td valign="top" rowspan="1" colspan="1">5.82</td><td valign="top" rowspan="1" colspan="1">4.69</td><td valign="top" rowspan="1" colspan="1">0.81</td></tr></tbody></table><table-wrap-foot><fn id="jmv26397-tbl2-note-0001"><p>Abbreviation: IC<sub>50</sub>, half maximal inhibitory concentration.</p></fn><fn id="jmv26397-tbl2-note-0002"><label>a</label><p>IC<sub>50</sub> was determined by Jeon et al<xref rid="jmv26397-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> except for nafamostat mesylate.</p></fn><fn id="jmv26397-tbl2-note-0003"><label>b</label><p>IC<sub>50</sub> was determined in this study.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>Interestingly, the IC<sub>50</sub> values of most drugs in our study increased in varying degrees in Calu&#x02010;3 cells (Figures&#x000a0;<xref rid="jmv26397-fig-0002" ref-type="fig-group">2A,C</xref>) (Tables&#x000a0;<xref rid="jmv26397-tbl-0001" ref-type="table">1</xref> and&#x000a0;<xref rid="jmv26397-tbl-0003" ref-type="table">3</xref>). Only six drugs showed decreases in IC<sub>50</sub> (Figure&#x000a0;<xref rid="jmv26397-fig-0002" ref-type="fig-group">2B</xref>) (Table&#x000a0;<xref rid="jmv26397-tbl-0002" ref-type="table">2</xref>): nafamostat mesylate, camostat mesylate, remdesivir, hydroxyprogesterone caproate, digitoxin, and cyclosporine. Although nafamostat mesylate and camostat mesylate were not selected as potent antiviral drug candidates in our earlier study, we compared the antiviral efficacy of these drugs at this time in between Vero and Calu&#x02010;3 cells following the discovery that TMPRSS2, a host protease necessary for priming viral spike glycoprotein, could be a target for COVID&#x02010;19 antiviral development.<xref rid="jmv26397-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> The discrepancy in IC<sub>50</sub> was specifically remarkable with nafamostat mesylate; the IC<sub>50</sub> decreased by approximately 6000 folds when the drug was used in the SARS&#x02010;CoV&#x02010;2&#x02010;infected Calu&#x02010;3 cells perhaps due to the dominant role of TMPRSS2&#x02010;dependent viral entry in the Calu&#x02010;3 human lung epithelial cells.<xref rid="jmv26397-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="jmv26397-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> In addition, the IC<sub>50</sub> of nafamostat mesylate was exceptionally low (0.0022&#x02009;&#x000b5;M), which indicates that nafamostat mesylate is approximately 600&#x02010;fold more potent than remdesivir in Calu&#x02010;3 cells. It became more apparent that blood clotting is one of the complicating manifestations in patients with COVID&#x02010;19,<xref rid="jmv26397-bib-0014" ref-type="ref">
<sup>14</sup>
</xref>, <xref rid="jmv26397-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> and nafamostat mesylate may play dual roles not only as an antiviral to block viral entry but also as an anticoagulant to remove blood clots frequently associated with acute respiratory distress syndrome. A recent case report on the treatment of three patients with COVID&#x02010;19 with nafamostat<xref rid="jmv26397-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> and other in vitro studies<xref rid="jmv26397-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="jmv26397-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> corroborated our findings. However, nafamostat has a short half&#x02010;life in the serum, thus requires continuous intravenous injection, which disables convenient administration for a large group of patients. Solving this disadvantage will increase the accessibility of more COVID&#x02010;19 patients to nafamostat treatment.</p><fig-group id="jmv26397-fig-0002" content-type="Figure" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Dose&#x02010;response curve (DRC) of the 24 drugs, nafamostat mesylate, and camostat mesylate. A, DRC of compounds with increased IC<sub>50</sub> value compared to those with Vero cells (fold change above 2). B, DRC of compounds with decreased IC<sub>50</sub> value compared to those with Vero cells (fold change less than 1). C, DRC of compounds with unchanged IC<sub>50</sub> value compared to those with Vero cells (fold change approximately 1). The red line indicates cell viability, and the blue line indicates inhibition of SARS&#x02010;CoV&#x02010;2 infection. SARS&#x02010;CoV&#x02010;2 infectivity was measured by immunofluorescence of SARS&#x02010;CoV&#x02010;2 N protein. Each point is a mean of duplicate experiments&#x02009;&#x000b1;&#x02009;standard deviation. IC<sub>50</sub>, CC<sub>50</sub>, and SI are noted below each graph. CC<sub>50</sub>, half maximal cytotoxic concentration; IC<sub>50</sub>, half maximal inhibitory concentration; SARS&#x02010;CoV&#x02010;2, severe acute respiratory syndrome coronavirus 2; SI, selective index</p></caption><fig fig-type="Figure" xml:lang="en" orientation="portrait" id="d40e922" position="anchor"><graphic id="nlm-graphic-3" xlink:href="JMV-9999-na-g002"/></fig><fig fig-type="Figure" xml:lang="en" orientation="portrait" id="d40e924" position="anchor"><graphic id="nlm-graphic-5" xlink:href="JMV-9999-na-g003"/></fig></fig-group><table-wrap id="jmv26397-tbl-0003" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 3</label><caption><p>List of drugs with unchanged IC<sub>50</sub> in Calu&#x02010;3 cells</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th valign="bottom" rowspan="1" colspan="1">Drug name</th><th valign="bottom" rowspan="1" colspan="1">IC<sub>50</sub> in Vero, &#x000b5;M<xref ref-type="fn" rid="jmv26397-tbl3-note-0002">a</xref>
</th><th valign="bottom" rowspan="1" colspan="1">IC<sub>50</sub> in Calu&#x02010;3, &#x000b5;M<xref ref-type="fn" rid="jmv26397-tbl3-note-0003">b</xref>
</th><th valign="bottom" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody valign="top"><tr><td valign="top" rowspan="1" colspan="1">Ouabain</td><td valign="top" rowspan="1" colspan="1">&#x0003c;0.1</td><td valign="top" rowspan="1" colspan="1">&#x0003c;0.1</td><td valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="top" rowspan="1" colspan="1">Eltrombopag</td><td valign="top" rowspan="1" colspan="1">8.27</td><td valign="top" rowspan="1" colspan="1">8.38</td><td valign="top" rowspan="1" colspan="1">1.01</td></tr><tr><td valign="top" rowspan="1" colspan="1">Loperamide hydrochloride</td><td valign="top" rowspan="1" colspan="1">9.27</td><td valign="top" rowspan="1" colspan="1">12.53</td><td valign="top" rowspan="1" colspan="1">1.35</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hexachlorophene</td><td valign="top" rowspan="1" colspan="1">0.9</td><td valign="top" rowspan="1" colspan="1">1.48</td><td valign="top" rowspan="1" colspan="1">1.64</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ivacaftor</td><td valign="top" rowspan="1" colspan="1">6.57</td><td valign="top" rowspan="1" colspan="1">11.55</td><td valign="top" rowspan="1" colspan="1">1.76</td></tr><tr><td valign="top" rowspan="1" colspan="1">Oxyclozanide</td><td valign="top" rowspan="1" colspan="1">3.71</td><td valign="top" rowspan="1" colspan="1">6.78</td><td valign="top" rowspan="1" colspan="1">1.83</td></tr></tbody></table><table-wrap-foot><fn id="jmv26397-tbl3-note-0001"><p>Abbreviation: IC<sub>50</sub>, half maximal inhibitory concentration.</p></fn><fn id="jmv26397-tbl3-note-0002"><label>a</label><p>IC<sub>50</sub> was determined by Jeon et al.<xref rid="jmv26397-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>
</p></fn><fn id="jmv26397-tbl3-note-0003"><label>b</label><p>IC<sub>50</sub> was determined in this study.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>In summary, we compared antiviral efficacy of the potential antiviral drug candidates against SARS&#x02010;CoV&#x02010;2 in between Vero and Calu&#x02010;3 cells and found that nafamostat mesylate is the most potent antiviral drug candidate in vitro. Importantly, nafamostat mesylate has been approved for human use in Japan and Korea for over a decade, thus it can be readily repurposed for COVID&#x02010;19 following phase II&#x02010;III clinical trials. Currently, a few clinical trials have been registered (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>). According to our results, although in vivo animal models are preferred experimental systems for evaluating antiviral efficacy, in vitro testing using human lung cells is a viable option in addition to the commonly used Vero or VeroE6 cells for assessment of antiviral efficacy when the animal models are not readily available.</p></sec><sec sec-type="COI-statement" id="jmv26397-sec-0080"><title>CONFLICT OF INTERESTS</title><p>The authors declare that there are no conflict of interests.</p></sec><sec id="jmv26397-sec-0090"><title>AUTHOR CONTRIBUTIONS</title><p>Conception: WSR and SK. Study design: MK, WSR, and SK. Participation in experiments and data collection: MK and SJ. Data acquisition, writing manuscript, and statistical analysis: MK and SK. All authors reviewed the manuscript and approved the final version.</p></sec></body><back><ack id="jmv26397-sec-0070"><title>ACKNOWLEDGMENTS</title><p>The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF&#x02010;2017M3A9G6068245 and NRF&#x02010;2020M3E9A1041756).</p></ack><sec id="jmv26397-sec-0110" sec-type="data-availability"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="jmv26397-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="jmv26397-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jmv26397-cit-0001">
<string-name>
<surname>Zhou</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>X&#x02010;L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X&#x02010;G</given-names>
</string-name>, et al. <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7798</issue>):<fpage>270</fpage>&#x02010;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jmv26397-cit-0002">
<string-name>
<surname>Gorbalenya</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Baric</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>The species Severe acute respiratory syndrome&#x02010;related coronavirus: classifying 2019&#x02010;nCoV and naming it SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Nat Microbiol</source>. <year>2020</year>;<volume>5</volume>(<issue>4</issue>):<fpage>536</fpage>&#x02010;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id>
<pub-id pub-id-type="pmid">32123347</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jmv26397-cit-0003">
<string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x02010;nCoV) in vitro</article-title>. <source xml:lang="en">Cell Res</source>. <year>2020</year>;<volume>30</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02010;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>
<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jmv26397-cit-0004">
<string-name>
<surname>Jeon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Identification of antiviral drug candidates against SARS&#x02010;CoV&#x02010;2 from FDA&#x02010;approved drugs</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>(<issue>7</issue>). <pub-id pub-id-type="doi">10.1128/AAC.00819-20</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jmv26397-cit-0005">
<string-name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chidekel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shaffer</surname>
<given-names>TH</given-names>
</string-name>. <article-title>Cultured human airway epithelial cells (Calu&#x02010;3): a model of human respiratory function, structure, and inflammatory responses</article-title>. <source xml:lang="en">Crit Care Res Pract</source>. <year>2010</year>;<volume>2010</volume>:<fpage>1</fpage>&#x02010;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1155/2010/394578</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jmv26397-cit-0006">
<string-name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Sch&#x000e4;fer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Remdesivir potently inhibits SARS&#x02010;CoV&#x02010;2 in human lung cells and chimeric SARS&#x02010;CoV expressing the SARS&#x02010;CoV&#x02010;2 RNA polymerase in mice</article-title>. <source xml:lang="en">bioRxiv</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.04.27.064279</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jmv26397-cit-0007">
<string-name>
<surname>Geleris</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Platt</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Observational study of hydroxychloroquine in hospitalized patients with COVID&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>2411</fpage>&#x02010;<lpage>2418</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2012410</pub-id>
<pub-id pub-id-type="pmid">32379955</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jmv26397-cit-0008">
<string-name>
<surname>Borba</surname>
<given-names>MGS</given-names>
</string-name>, <string-name>
<surname>Val</surname>
<given-names>FFA</given-names>
</string-name>, <string-name>
<surname>Sampaio</surname>
<given-names>VS</given-names>
</string-name>, et al. <article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS&#x02010;CoV&#x02010;2) infection</article-title>. <source xml:lang="en">JAMA Netw Open.</source>
<year>2020</year>;<volume>3</volume>(<issue>4</issue>):<elocation-id>e208857</elocation-id>
<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jmv26397-cit-0009">
<string-name>
<surname>Cao</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A trial of lopinavir&#x02010;ritonavir in adults hospitalized with severe COVID&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med. 2020</source>. <year>2020</year>;<volume>382</volume>(<issue>19</issue>):<fpage>1787</fpage>&#x02010;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jmv26397-cit-0010">
<string-name>
<surname>Beigel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Tomashek</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Dodd</surname>
<given-names>LE</given-names>
</string-name>, et al. <article-title>Remdesivir for the treatment of COVID&#x02010;19&#x02014;preliminary report</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jmv26397-cit-0011">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>(<issue>2</issue>):<fpage>271</fpage>&#x02010;<lpage>280.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>
<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jmv26397-cit-0012">
<string-name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein&#x02010;mediated membrane fusion using the split&#x02010;protein&#x02010;based cell&#x02010;cell fusion assay</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2016</year>;<volume>60</volume>(<issue>11</issue>):<fpage>6532</fpage>&#x02010;<lpage>6539</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01043-16</pub-id>
<pub-id pub-id-type="pmid">27550352</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jmv26397-cit-0013">
<string-name>
<surname>Kawase</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shirato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>van der Hoek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Taguchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</string-name>. <article-title>Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry</article-title>. <source xml:lang="en">J Virol</source>. <year>2012</year>;<volume>86</volume>(<issue>12</issue>):<fpage>6537</fpage>&#x02010;<lpage>6545</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00094-12</pub-id>
<pub-id pub-id-type="pmid">22496216</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jmv26397-cit-0014">
<string-name>
<surname>Klok</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Kruip</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van der Meer</surname>
<given-names>NJM</given-names>
</string-name>, et al. <article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID&#x02010;19</article-title>. <source xml:lang="en">Thromb Res</source>. <year>2020</year>;<volume>191</volume>:<fpage>145</fpage>&#x02010;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.013</pub-id>
<pub-id pub-id-type="pmid">32291094</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jmv26397-cit-0015">
<string-name>
<surname>Poissy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goutay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Caplan</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Pulmonary embolism in COVID&#x02010;19 patients: awareness of an increased prevalence</article-title>. <source xml:lang="en">Circulation</source>. <year>2020</year>;<volume>142</volume>:<fpage>184</fpage>&#x02010;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047430</pub-id>
<pub-id pub-id-type="pmid">32330083</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jmv26397-cit-0016">
<string-name>
<surname>Jang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rhee</surname>
<given-names>J&#x02010;Y</given-names>
</string-name>. <article-title>Three cases of treatment with nafamostat in elderly patients with COVID&#x02010;19 pneumonia who need oxygen therapy</article-title>. <source xml:lang="en">Int J Infect Dis</source>. <year>2020</year>;<volume>96</volume>:<fpage>500</fpage>&#x02010;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.072</pub-id>
<pub-id pub-id-type="pmid">32470602</pub-id></mixed-citation></ref><ref id="jmv26397-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jmv26397-cit-0017">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Drosten</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>P&#x000f6;hlmann</surname>
<given-names>S</given-names>
</string-name>. <article-title>Nafamostat mesylate blocks activation of SARS&#x02010;CoV&#x02010;2: new treatment option for COVID&#x02010;19</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>(<issue>6</issue>). <pub-id pub-id-type="doi">10.1128/AAC.00754-20</pub-id>
</mixed-citation></ref><ref id="jmv26397-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jmv26397-cit-0018">
<string-name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kiso</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sakai&#x02010;Tagawa</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>The anticoagulant nafamostat potently inhibits SARS&#x02010;CoV&#x02010;2 S protein&#x02010;mediated fusion in a cell fusion assay system and viral infection in vitro in a cell&#x02010;type&#x02010;dependent manner</article-title>. <source xml:lang="en">Viruses</source>. <year>2020</year>;<volume>12</volume>(<issue>6</issue>):<fpage>629</fpage>
<pub-id pub-id-type="doi">10.3390/v12060629</pub-id>
</mixed-citation></ref></ref-list></back></article>